Oncology Institute financial statements

NASDAQ:TOI · Nasdaq · Healthcare

$5.13+0.00%

2026-08-04 close

Oncology Institute's published financial data is dated 2026-10-04. 2024 revenue was $393M. 2024 operating profit was −$60M.

Reported results

Financial safety

Reference indicatorAs of 2024

Distress zoneFinancial-metric reference signal

Altman Z'' zoneZ'' -4.01

Distress

Grey

Safe

The marker shows the current Z'' value within the displayed zones.

Altman Z'': -4.01
Beneish M-Score: -3.26
Sloan accrual: -22.07%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

3/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score3/9

Profitability

Positive ROANot passed
Positive OCFNot passed
Improving ΔROAPass
Accruals (OCF > net income)Pass

Leverage & liquidity

Lower debtNot passed
Higher current ratioNot passed
No new sharesNot passed

Efficiency

Higher gross marginNot passed
Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin: -15.3%
Interest coverage: -8x
Return on equity (ROE): -1,801.7%

Operating margin −5pp

Operating loss

Interest coverageBase -8x-10.6x

Return on equity (ROE)Base -1,801.7%-2,432%

Revenue −15%

Interest coverage risk

Interest coverageBase -8x-6.8x

Return on equity (ROE)Base -1,801.7%-1,632.7%

Interest rate +2pp

Interest coverage risk

Interest coverageBase -8x-5.5x

Return on equity (ROE)Base -1,801.7%-1,978.2%

Interest coverage limit

Already below the limit by 17.2pp

Interest coverage limit at an operating margin of 1.9%

Interest expense coverage threshold

Quantus Signal · live data · not investment advice · Privacy Policy